Diabetes
How risky is diagnosed NAFLD for cirrhosis and liver cancer?
Open access · cc by · source: Europe PMC
In ~19 million European adults, coded NAFLD/NASH carried ~4.7× cirrhosis and ~3.5× HCC hazard vs matched controls, with diabetes the strongest predictor.
Study at a glance
- Design
- Cohort — Matched cohort in four European primary-care databases; Cox HRs pooled by meta-analysis
- N
- N=136703 · 136,703 coded NAFLD/NASH within 18,782,281 adults
- Population
- Adults with coded NAFLD/NASH vs matched non-NAFLD controls in UK/NL/Italy/Spain
- Outcome
- Incident cirrhosis and HCC diagnoses; predictors including diabetes
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Among 136,703 NAFLD/NASH patients, cirrhosis HR 4.73 and HCC HR 3.51 vs controls; risk higher with NASH or high-risk Fib-4; diabetes strongly predicted advanced liver diagnoses.
Methodology
They identified NAFLD/NASH diagnoses in four primary-care databases, matched each case to up to 100 controls, and pooled age/smoking-adjusted Cox HRs for cirrhosis and HCC.
Limitations
Coded diagnoses under-ascertain NAFLD; observational HRs are not biopsy-proven natural history or treatment effects.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.